MUVON Therapeutics
CompanySwitzerland
MUVON Therapeutics develops one asset, in phase 2 (muscle precursor cell (MPC)-based tissue-engineered therapy in female stress urinary incontinence). Mostly cell therapy acting on stem cell maintenance; based in Switzerland.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1muscle precursor cell (MPC)-based tissue-engineered therapy
Autologous muscle precursor cell-based tissue-engineered therapy to regenerate sphincter muscle tissue
Phase 2, Cell therapy, Stem cell maintenance, female stress urinary incontinence, stress urinary incontinence
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies6